http://www.laboratorytalk.com/news/aby/aby000.html Ablynx news releases on Laboratorytalk en-gb Copyright (C)2008 Pro-Talk Ltd. All rights reserved. Mon, 07 Jul 2008 08:00:00 UT Mon, 07 Jul 2008 08:00:00 UT http://www.pro-talk.com/images/protalklogo90.gif http://www.pro-talk.com/ 90 79 Ablynx has initiated a double-blind, randomised, placebo-controlled multiple dose Phase Ib study for its novel anti-thrombotic that selectively targets von Willebrand (vWF) factor Fri, 30 May 2008 08:00:00 UT Ablynx http://www.laboratorytalk.com/news/aby/aby103.html Ablynx and Boehringer Ingelheim sign $265 million research and licensing agreement to develop new Alzheimer's treatments Tue, 09 Jan 2007 08:00:00 UT Ablynx http://www.laboratorytalk.com/news/aby/aby102.html Nanobody technology has been used to rapidly identify a highly diverse and potent panel of Nanobodies against one of the targets exclusive to the collaboration, triggering a milestone payment Thu, 14 Dec 2006 08:00:00 UT Ablynx http://www.laboratorytalk.com/news/aby/aby101.html Ablynx enters deal with Wyeth Pharmaceuticals to discover, develop and commercialise Nanobodies directed at the tumour necrosis factor alpha protein and its receptors Tue, 14 Nov 2006 08:00:00 UT Ablynx http://www.laboratorytalk.com/news/aby/aby100.html